Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma.
dc.contributor.author | Armstrong, Anne C | |
dc.contributor.author | Dermime, Said | |
dc.contributor.author | Mulryan, Kate | |
dc.contributor.author | Stern, Peter L | |
dc.contributor.author | Bhattacharyya, Tapan | |
dc.contributor.author | Hawkins, Robert E | |
dc.date.accessioned | 2009-08-24T16:10:55Z | |
dc.date.available | 2009-08-24T16:10:55Z | |
dc.date.issued | 2009-08-24T16:10:55Z | |
dc.identifier.citation | Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma., 27 (3):227-31 J. Immunother. | en |
dc.identifier.issn | 1524-9557 | |
dc.identifier.pmid | 15076140 | |
dc.identifier.uri | http://hdl.handle.net/10541/78365 | |
dc.description.abstract | There is extensive interest in idiotypic vaccination as a treatment of lymphoma. An alternative approach is the adoptive transfer of in vitro generated T cells. This strategy has been used to treat posttransplantation EBV-related diseases. The ability to generate in vitro T cells to peptides derived from immunoglobulin idiotypes raises the possibility of directly using such cells as a treatment of lymphoma. Investigating the adoptive transfer of specific T cells to idiotype derived peptides in a murine lymphoma model is therefore an important part of the clinical translation of this alternative approach. We have generated an idiotype-specific T cell line, able to recognise a defined, naturally processed idiotype-derived epitope. This line has been used to successfully treat mice with disseminated lymphoma supporting the clinical use of idiotype specific T cells. | |
dc.language.iso | en | en |
dc.subject | Cell Line Tumour | en |
dc.subject.mesh | Adenoviridae | |
dc.subject.mesh | Adoptive Transfer | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Cell Division | |
dc.subject.mesh | Cell Line, Tumor | |
dc.subject.mesh | Chromium | |
dc.subject.mesh | Enzyme-Linked Immunosorbent Assay | |
dc.subject.mesh | Epitopes | |
dc.subject.mesh | Female | |
dc.subject.mesh | Immunoglobulin Fragments | |
dc.subject.mesh | Immunoglobulin Idiotypes | |
dc.subject.mesh | Immunoglobulins | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Immunotherapy, Adoptive | |
dc.subject.mesh | Interferon-gamma | |
dc.subject.mesh | Lymphoma | |
dc.subject.mesh | Lymphoma, B-Cell | |
dc.subject.mesh | Mice | |
dc.subject.mesh | Mice, Inbred BALB C | |
dc.subject.mesh | Peptides | |
dc.subject.mesh | Reverse Transcriptase Polymerase Chain Reaction | |
dc.subject.mesh | T-Lymphocytes | |
dc.subject.mesh | Time Factors | |
dc.title | Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. | en |
dc.contributor.department | Cancer Research UK Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK. | en |
dc.identifier.journal | Journal of Immunotherapy | en |
html.description.abstract | There is extensive interest in idiotypic vaccination as a treatment of lymphoma. An alternative approach is the adoptive transfer of in vitro generated T cells. This strategy has been used to treat posttransplantation EBV-related diseases. The ability to generate in vitro T cells to peptides derived from immunoglobulin idiotypes raises the possibility of directly using such cells as a treatment of lymphoma. Investigating the adoptive transfer of specific T cells to idiotype derived peptides in a murine lymphoma model is therefore an important part of the clinical translation of this alternative approach. We have generated an idiotype-specific T cell line, able to recognise a defined, naturally processed idiotype-derived epitope. This line has been used to successfully treat mice with disseminated lymphoma supporting the clinical use of idiotype specific T cells. |